StreetAlpha.app
Home › Stocks › ACIU

AC Immune SA (ACIU)

$2.11
▲ +0.96%
LAST CLOSE · NOV 17

AC Immune develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, based in Lausanne, Switzerland. It last closed at $2.11 on Nov 17, up 0.96% on the day.

AI Auto Pilots
Is ACIU in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
CHF 3.6M
−86.9% vs a year ago
Net income
−CHF 70.4M
−1971.6% margin
Free cash flow
−CHF 70.2M
−1963.7% margin
Operating margin
−1940.1%
−CHF 69.3M operating income
Balance sheet
Cash & equivalents
CHF 26.8M
At Dec 31
Shareholder equity
CHF 44.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: CHF 0CHF 0FY2021FY2022: CHF 3.9MCHF 3.9MFY2022FY2023: CHF 14.8MCHF 14.8MFY2023FY2024: CHF 27.3MCHF 27.3MFY2024FY2025: CHF 3.6MCHF 3.6MFY2025

From ACIU's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 13). Last 12 months adds up the four latest quarters. Figures are in CHF. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ACIU in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 279.1% upside

Based on 1 analyst who set a price target on ACIU in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $2.11.

Low $8.00Avg $8.00High $8.00
Blue marker: last close $2.11
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
BTIGReiterated
Aug 20Buy$8
DateFirmActionRatingPrice target
Aug 20BTIGReiteratedBuy$8
Loading…

Technical Analysis

ACIU · as of the Nov 17 close · updated after every close
Downtrend

The stock is 7% below its 20 day and 17% below its 50 day average. It is 26% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the swing low (Jun 9) at $2.10, and the nearest resistance the Pivot R1 at $2.15.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 6.9%/day
Key levels
$3.9052 week high+84.8%
$2.65200 day average+25.6%
$2.48100 day average+17.5%
$2.4750 day average+17.1%
$2.34Swing high (Jul 22)+10.9%
$2.2620 day average+7.1%
$2.15Pivot R1+1.9%
$2.11Last close
$2.10Swing low (Jun 9)−0.5%
$2.09Pivot−0.9%
$2.05Pivot S1−2.8%
$2.0252 week low−4.3%
Indicators
RSI (14)41.33Middle of its rangeNeutral
MACD-0.09Below its signal lineBearish
Stochastic18.3Near the bottom of its rangeOversold
ADX (14)19.7No clear trend
Williams %R-81.7Oversold below −80, overbought above −20Oversold
CCI (20)-98.5Oversold below −100, overbought above 100Neutral
Rate of change+1.0%Change over 10 sessionsBullish
ATR (14)$0.15Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACIU

What happened before

See how ACIU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ACIU usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ACIU has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ACIU in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACIU Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●18 buying vs 18 selling
  • ▼Shares held by funds -1.3%
  • ▼Funds holding -3
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding4043−7.0%
In funds' top 1000–
Held by funds–––
New / increased5 / 136 / 10+12.5%
Reduced / sold out11 / 715 / 9−25.0%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACIU institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACIU is in one of them and how their past ACIU trades turned out.

ACIU in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACIU in an article yet. Here's the latest on the wider market.

About AC Immune SA

AC Immune is a biopharmaceutical company based in Lausanne, Switzerland, that develops treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its candidates include active immunotherapies, which are biologic treatments, and small molecule drugs designed to act inside brain cells. The company uses its own technology platforms to design these candidates and has partnered with large global pharmaceutical companies on parts of its pipeline.

Headquarters
1015 Lausanne, Switzerland